Business Context and Reporting Period
This Form 8-K was filed by Mainz Biomed N.V. (doing business as Quantum Cyber N.V.) on March 17, 2026. The registrant is incorporated in The Netherlands and trades on the Nasdaq Capital Market under the symbol QUCY. The company is designated as an emerging growth company.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The report focuses on corporate events rather than periodic financial performance data.
Material Changes and Events
- Strategic Realignment: The company announced a strategic alignment with the Trump Administration's National Cyber Security Framework, targeting acquisitions in the quantum and cyber defense sectors.
- Private Placement Update: The company received a pre-payment for the second tranche of a private placement previously announced on February 13, 2026, with investor David E. Lazar.
- Closing Timeline: The closing of the second tranche is expected to occur prior to April 2026, subject to stockholder approvals and customary closing conditions.
Guidance, Outlook, and Risks
Management indicated that the use of proceeds from the private placement will support the company's strategic initiatives. The filing includes forward-looking statements regarding the timing and completion of the private placement. Material risks include the failure to obtain required stockholder approvals, the inability to satisfy closing conditions, and potential deviations in the intended use of proceeds.
Investor Verification Checklist
- Verify the status of stockholder approvals required for the second tranche of the private placement.
- Confirm the final closing date of the private placement with investor David E. Lazar.
- Review the attached press release (Exhibit 99.1) for specific details on the acquisition targets in the quantum and cyber defense sectors.
- Monitor subsequent filings for the official closing of the private placement and the issuance of new shares.